Predictors of no reflow/slow flow during primary percutaneous coronary intervention in patients with acute myocardial infarction  by Sabin, P. et al.
GPIIb-IIIa administrated within 2 weeks before study, CABGwithin
2 months or PCI within 6 months before study, STEMI undergone
thrombolytic undergone within 48 h, unprotected LMCA >50%
stenosis, sever coronary calciﬁcation, target lesion in SVG, acute
STEMI with a primary PCI strategy and contraindication to antic-
oagulant therapy.
The patients were randomized alternately to intracoronary and
intravenous tiroﬁban. Fifty seven patients were given intracoron-
ary tiroﬁban and taken as study population and ﬁfty eight patients
were given intravenous tiroﬁban and taken as control population.
In the control group, tiroﬁban was given intravenously as a bolus
(10 mg/kg over 3 min) followed by maintenance intravenous infu-
sion at 0.15 mg/kg/min for 36 h. In the study group, tiroﬁban was
administered as an intracoronary bolus injection (10 mg/kg over
3 min) followed by maintenance intravenous infusion at 0.15 mg/
kg/min for 36 h. All patients were evaluated at the end of 14 and 30
day period. Flow in the PCI-targeted coronary arterieswas assessed
by thrombolysis in myocardial infarction (TIMI) ﬂowgrade. Left
ventricular ejection fraction (LVEF) was assessed by standard 2-
dimensional echocardiography at 14 and 30 days after PCI. Major
adverse cardiac events (MACE), such as death, non-fatal myocar-
dial infarction or re-infarction, revascularization of targeted ves-
sels, or worsening left ventricular dysfunction, were also assessed
at 14 days and 30 days following PCI. Major and minor bleeding
complications within 14 days also evaluated.
Results: Comparedwith the control group, the study group showed
better TIMI ﬂow grades and TIMI myocardial perfusion grades
(TMPG) immediately after PCI ( p = 0.016 and 0.026, respectively).
The 14-day composite MACE rate was lower in the study group
(3.5% vs 17.5%, p = 0.030), but was similar between the 2 groups at
30 days following PCI (7.0% vs 1.7%, p = 0.350). The LVEF in the study
group was higher than in the control group 30 days following PCI
(67.4  6.2% vs 60.7  4.6%, p = 0.033). The 14-day bleeding compli-
cation ( p = 0.201) was similar between the 2 groups.
Conclusion: In patients with ACS undergoing primary PCI, intra-
coronary bolus administration of tiroﬁban is superior to intrave-
nous bolus injection for improving coronary ﬂow, myocardial
perfusion and short-term clinical outcome.
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Background: The aim of treatment for acute myocardial infarction
(AMI) is to restore full antegrade blood ﬂow in the infarct-related
artery and minimize ischemic damage to the myocardium. How-
ever, primary PCI is associated with a serious problem known as
the no-reﬂowphenomenon (thrombolysis inmyocardial infarction
(TIMI) ﬂow ≤2), which occurs in 5–25% of cases.
Methods: This is a case control study of all consecutive patients
with AMI admitted at our institution and underwent primary PCI
from August 2014 to February 2015 based on ACC/AHA guidelines.
Results: In the 181 patients who had undergone primary PCI, 47
(25.9%) showed an angiographic no-reﬂow phenomenon.
Multiple stepwise logistic regression analysis identiﬁed that reper-
fusion time >6 h (OR = 13.844, 95%CI 3.214–59.636, p = <0.001), age
>60 years (OR = 8.886, 95%CI 2.145–36.80, p = 0.003), a long target
lesion (OR = 8.637, 95%CI 1.975–37.768, p = 0.004), low initial TIMI
ﬂow (≤1) (OR = 20.861, 95%CI 1.739–250.290, p = 0.017) were the
independent predictors of the no-ﬂow phenomenon in our study.
Conclusions: In conclusion, the pathogenesis of no-reﬂow phe-
nomenon is complex and multifactorial. In the light of our recent
study, patients who are likely to develop the no-reﬂow phenom-
enon after primary PCI can be predicted by simple clinical and
angiographic features.
It is important to avoid or minimize trauma to the vessel, avoid
repetitive balloon dilatations and use the shortest stent if possible.
Because most patients with AMI have a combination of these
factors, combined treatment strategies should be preferred.
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Background: Acute myocardial infarction below 45 years of age
constitutes a speciﬁc subset of population having different risk
factors and clinical features and prognosis as compared to older
patients. The protection offered by young age has been slowly
taken away by the increased prevalence of risk factors for CHD in
adolescents such as smoking, obesity, and lack of physical activity.
Objective: The purpose of this study is to describe the risk factors,
clinical features, angiographic patterns and outcomes in AMI in
young patients (<45 years) and to compare the samewith the older
subjects (>45 years) and to study the various complications in 7
days follow up.
Material andmethods: The present studywas carried out at the LPS
institute of cardiology Kanpur. Total 150 cases of acute myocardial
infarction admitted in ICCU during 1st January 2014 to 1st January
2015 were enrolled and were categorized in two groups: (a) Group I
– age <45 years, b) Group II age ≥45 years. Fasting blood glucose,
fasting lipid proﬁle, serial ECGs and the cardiac enzymes (troponin
T and I) were evaluated. The risk factors which were studied were
hypertension, diabetes mellitus, smoking habits, overweight,
waist to hip ratio, hyperlipidemia and family history.
Results: Mean age of the cases was 38  7 and 68.2  5 in group I
and II respectively. The male and female ratio was 3:1 in group I
and 1.5:1 in group II. Atypical chest pain, sweating, dyspnea and
giddiness were less frequently in the younger group with AMI than
group II. Younger subjects arriving within 6 h of chest pain was
signiﬁcantly more as in no compared to older subjects (49/65 i.e.
75% vs 38/85 i.e. 45%, p = <0.05). Tobacco consumption was the
most common risk factor in group I (71% vs 25% in group II).
Anterior wall MI, (including lateral MI) was the most common
presentation present in 57.64% of the patients in group I vs 45%
in group II. The incidence of major complications like congestive
cardiac failure, arrhythmias, cardiogenic shock were signiﬁcantly
less in the younger group (50%, 20%, 5%) as compared to (75%, 55%,
15%) respectively in older group. Mortality was signiﬁcantly lower
in group (I) than (group II) 5% vs 20%. Angiography results showed
SVD in 48% patients in group I vs 25% in group II. TVD was present
in only 3% of the patients in group I vs 27% in group II. LMCA was
involved in 3% in group I vs 12% in group II. Normal or nonsigni-
ﬁcant coronaries were present in 18% in group I vs 2% in group II.
From these results we conclude that Myocardial infarction before
age 45 is a disease of men. Young patients tend to have less
extensive coronary artery lesions. Very low prevalence of Triple-
vessel disease is present. Young patients have more favourable in
hospital prognosis than their older counterparts. A sizeable pro-
portion of patients will have normal coronary arteries. Health
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